Adiponectin, ICAM-1, VCAM-1 Levels and Metabolic Syndrome in Obese Adolescents

NCT05685017 | Completed DMC

• 1 other identifier: Secondary ID
• Study Type: observational
• Target: 125
• Locations: 1 country
• Sites: 1

Brief Summary

Adipose tissue secreting a number of adipokines which regulate insulin sensitivity, energy metabolism and vascular homeostasis, so the dysfunction of adipose tissue is linked with the incidence of obesity accompanied with insulin resistance, hypertension and cardiovascular disease (1). Obesity is known to alters the expression of adipokines due to the adipose tissue hypertrophy (2), including adiponectin, in which able to exert a potent anti-inflammatory and vascular protective effect (2). It has been proposed that adiponectin acts to prevent the vascular dysfunction due to obesity and diabetes by improves insulin sensitivity and metabolic profiles to reduce the risk factors for cardiovascular disease and protects the vasculature through its pleiotropic actions on endothelial cells, endothelial progenitor cells, smooth muscle cells and macrophages (1). The concentrations of adiponectin of 5 to 25 mg/mL had a significant inhibitory effect on the expression of monocyte adhesion and adhesion molecule induced by TNF-α in vitro. Atherosclerosis is an inflammatory disease in which adhesion molecules on arterial endothelial cells are responsible for the accumulation of monocytes/macrophages and T lymphocytes. While obesity is low-grade inflammation in which make a contribution on endothelial dysfunction by increasing the oxygen-derived free radicals (ROS) due to adipocyte hypertrophy, leads to an endoplasmic reticulum (ER) stress and mitochondrial dysfunction (3). Adiponectin is accumulated in the vasculature, and it reduced on obesity due to suppression by TNF-α and lead to adiponectin-deficiency which stimulate the significant increases of Vascular cell adhesion protein 1 (VCAM-1) and Intercellular Adhesion Molecule 1 (ICAM-1) or known as CD54 in aortic intima (4). Here we investigate the level of adiponectin, ICAM-1, VCAM-1 with the incidence of MetS in obese adolescents.

Conditions

Obesity; Abdominal Obesity; Metabolic Syndrome; Hypertension; Hypertriglyceridemia; HDL Cholesterol, Low Serum; Hyperglycemia

Outcome Measures

Primary Outcomes (3)

• ICAM-1 levels

  Intercellular Adhesion Molecule 1 also known as CD54 was measured Human intercellular adhesion molecule 1 Elisa kit (Bioassay Technology Laboratory), stated as pg/ml (mean +/- SD)

  4 months

• VCAM-1

  Vascular cell adhesion molecule 1 was measured using Human vascular cell adhesion molecule-1 Elisa kit (Bioassay Technology Laboratory), stated as pg/ml (mean +/- SD)

  4 months

• Adiponectin

  For Adiponectin, ICAM-1 and VCAM-1 analysis, the blood that has been taken was not immediately analysed. The blood was centrifuged to remove the serum, and then stored at -70°C until the analysis was performed in the laboratory. Adiponectin was analysed using using Human Adiponectin Elisa kit (Bioassay Technology Laboratory), stated as ng/ml (mean +/- SD)

  4 months

Secondary Outcomes (2)

• Physical Measurements: Body weight

  4 months

• Physical Measurements: Body height

  4 months

Other Outcomes (7)

• Physical Measurements: Waist Circumference

  4 months

• Physical Measurements: Hip Circumference

  4 months

• Blood Pressure: Systole and diastole

  4 months

Study Arms (1)

Metablic syndrome vs. non-metabolic syndrome

Obese adolescents were grouped on MetS vs. non-MetS based on The International Diabetic Federation criteria

Diagnostic Test: Nur Aisiyah Widjaja

Interventions

Nur Aisiyah Widjaja DIAGNOSTIC_TEST

Blood analysis for ICAM-1, VCAM-1, blood fasting insulin, lipid profile, fasting blood glucose and adiponectin investigation

Also known as: Suhasta Nova, Leonardo Alexander Caesar

Metablic syndrome vs. non-metabolic syndrome

Eligibility Criteria

• Age: 13 Years - 18 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

The subjects were obese adolescents who were studied at Junior and Senior High School in Surabaya and Sidoarjo, East Java, Indonesia

You may qualify if:

• Obesity
• Healthy (no medication treatment)

You may not qualify if:

• Taking corticosteroids or dyslipidemia medication
• Smoking or drinking (consuming alcohol)
• Taking antibiotics or hormonal therapy
• Autoimmune disease
• Endocrinology disorders

Sponsors & Collaborators

• Universitas Airlangga: lead

Study Sites (1)

Institute of Tropical Disease (ITD) Airlangga University, Campus C

Surabaya, East Java, 60286, Indonesia

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood samples were withdrawn via vena cubitus as much as 5 ml by the trained analyst, and placed on vacutainer with EDTA. After that, the vacutainer was replaced in icebox to transport to the laboratory. Blood analysis including: lipid profile, fasting blood glucose, fasting insulin and adiponectin using the ELISA method in the laboratory. Intercellular Adhesion Molecule-1 (ICAM-1) was analyzed using Human intercellular adhesion molecule 1 Elisa kit (Bioassay Technology Laboratory). while sVCAM-1 was analysed using Human vascular cell adhesion molecule-1 Elisa kit (Bioassay Technology Laboratory).

MeSH Terms

Conditions

Obesity; Obesity, Abdominal; Metabolic Syndrome; Hypertension; Hypertriglyceridemia; Hypoalphalipoproteinemias; Hyperglycemia

Condition Hierarchy (Ancestors)

Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Insulin Resistance; Hyperinsulinism; Glucose Metabolism Disorders; Metabolic Diseases; Vascular Diseases; Cardiovascular Diseases; Hyperlipidemias; Dyslipidemias; Lipid Metabolism Disorders; Hypolipoproteinemias; Lipid Metabolism, Inborn Errors; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

• Andy Darma, Paediatrician

  Child Health Departement Airlangga University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Target Duration: 1 Month
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator on Gastroenterology

Study Record Dates

• First Submitted: January 1, 2023
• First Posted: January 13, 2023
• Study Start: October 1, 2019
• Primary Completion: January 30, 2020
• Study Completion: June 30, 2020
• Last Updated: January 13, 2023

Record last verified: 2023-01

Data Sharing

• IPD Sharing: Will not share

Locations

ID (1)